Novartis Ag (NVS) Beginning Cash Balance (2017 - 2025)
Novartis Ag (NVS) posted Beginning Cash Balance of $7.1 billion for Q2 2025, down 25.38% sequentially from $9.5 billion in Q2 2024, and down 25.38% YoY from $9.5 billion in Q2 2024.
Novartis Ag (NVS) Beginning Cash Balance (2017 - 2025) Analysis & Trends
Novartis Ag (NVS) has 5 years of Beginning Cash Balance data on file, last reported at $7.1 billion in Q2 2025.
- Quarterly Beginning Cash Balance fell 25.38% year-over-year to $7.1 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $29.2 billion (down 1.71% YoY) and the FY2017 annual result came in at $7.0 billion, up 49.91% from the prior year.
- Beginning Cash Balance eased to $7.1 billion in Q2 2025 per NVS's latest filing, from $9.5 billion in the prior quarter.
- The five-year high for Beginning Cash Balance was $9.5 billion in Q2 2024, with the low at $7.1 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 7.07 Bn |
| Jun 30, 2025 | 7.07 Bn |
| Jun 30, 2024 | 9.47 Bn |
| Jun 30, 2024 | 9.47 Bn |
| Jun 30, 2019 | 6.81 Bn |
| Jun 30, 2019 | 6.81 Bn |
| Jun 30, 2018 | 5.81 Bn |
| Jun 30, 2018 | 5.81 Bn |
| Jun 30, 2017 | 7.57 Bn |
| Jun 30, 2017 | 7.57 Bn |